Clinical data at the time of treatment
| Characteristic . | . | Range . |
|---|---|---|
| No. of patients | 100 | NA |
| Gender: male/female | 57/43 | NA |
| Age (y) | 16 | 1-72 |
| Neutrophil count (×109/L) | 0.2 | 0-0.5 |
| Platelet count (×109/L) | 5 | 0-40 |
| Infection (yes/no) | 37/58 | NA |
| Hemorrhage (yes/no) | 43/53 | NA |
| Interval from diagnosis to treatment (d) | 22 | 0-460 |
| Response | ||
| No response | 23 | NA |
| Partial response | 29 | NA |
| Complete response | 48 | NA |
| No. of patients with clonal evolution | 8 | NA |
| No. of patients with relapse | 9 | NA |
| Interval from treatment to relapse (d) | 335 | 125-1032 |
| Deaths | 12 | NA |
| Cause of death | ||
| Sepsis | 8 | NA |
| Hemorrhage | 4 | NA |
| Follow-up of surviving patients (d) | 1424 | 81-2889 |
| Follow-up of deceased patients (d) | 84 | 16-1132 |
| Characteristic . | . | Range . |
|---|---|---|
| No. of patients | 100 | NA |
| Gender: male/female | 57/43 | NA |
| Age (y) | 16 | 1-72 |
| Neutrophil count (×109/L) | 0.2 | 0-0.5 |
| Platelet count (×109/L) | 5 | 0-40 |
| Infection (yes/no) | 37/58 | NA |
| Hemorrhage (yes/no) | 43/53 | NA |
| Interval from diagnosis to treatment (d) | 22 | 0-460 |
| Response | ||
| No response | 23 | NA |
| Partial response | 29 | NA |
| Complete response | 48 | NA |
| No. of patients with clonal evolution | 8 | NA |
| No. of patients with relapse | 9 | NA |
| Interval from treatment to relapse (d) | 335 | 125-1032 |
| Deaths | 12 | NA |
| Cause of death | ||
| Sepsis | 8 | NA |
| Hemorrhage | 4 | NA |
| Follow-up of surviving patients (d) | 1424 | 81-2889 |
| Follow-up of deceased patients (d) | 84 | 16-1132 |
NA indicates not applicable.